Publications by authors named "E Samalin"

Claim this Profile
M
Methodological approach to optimize a step-by-step deterministic linkage of SNDS data with a clinical database (FREGAT) of gastric/gastroesophageal junction adenocarcinoma in France: Pitfalls and learnings.
Magali Laborey, Audrey Lajoinie, Jonatan Freilich, Emmanuelle Samalin, Olivier Bouché

PLoS One· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.
Aziz Zaanan, Olivier Bouché, Christelle de la Fouchardière, Karine Le Malicot, Simon Pernot, Emmanuelle Samalin

Lancet Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regorafenib combined with irinotecan as second-line treatment in metastatic gastro-oesophageal adenocarcinomas: results of PRODIGE 58-UCGI35-REGIRI Unicancer randomised phase II study.
E Samalin, L Evesque, A Turpin, C De La Fouchardiere, F Khemissa-Akouz

ESMO Open· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early palliative care and overall survival in patients with metastatic upper gastrointestinal cancers (EPIC): a multicentre, open-label, randomised controlled phase 3 trial.
Antoine Adenis, Arlette Da Silva, Meher Ben Abdelghani, Vincent Bourgeois, Emilie Bogart, Emmanuelle Samalin

EClinicalMedicine· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus modified docetaxel, cisplatin, and fluorouracil as first-line treatment for advanced anal cancer (SCARCE C17-02 PRODIGE 60): a randomised, non-comparative, phase 2 study.
Stefano Kim, Francois Ghiringhelli, Christelle de la Fouchardière, Ludovic Evesque, Denis Smith, Emmanuelle Samalin

Lancet Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis